John Hood, Endeavor BioMedicines CEO
April 24, 2024 07:30 AM EDTUpdated 08:41 AM
Financing
Startups

En­deav­or Bio­Med­i­cines snags $132M for Phase 2 fi­bro­sis drug, ADC can­di­date

Kyle LaHucik

Biotech Correspondent

San Diego biotech En­deav­or Bio­Med­i­cines is on a tear.

The start­up has se­cured a $132.5 mil­lion Se­ries C af­ter hir­ing four C-suite lead­ers,

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

FDA re­jects Stealth's rare dis­ease drug, but of­fers po­ten­tial for ac­cel­er­at­ed ap­proval

Up­dat­ed: Trump ad­min­is­tra­tion halts more than $750M in funds for Mod­er­na’s bird flu vac­cine

Pep­Gen ditch­es Duchenne pro­grams af­ter mid-stage fail, switch­es to pre­vi­ous­ly halt­ed mus­cle wast­ing ther­a­py

Ex­clu­sive: Move­ment dis­or­der biotech Vi­ma steps on­to scene with $60M

Oric locks down cash for Phase 3 prostate can­cer tri­al with ear­ly da­ta in hand

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times